Clinical Trial Update: A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema [Phase 3]

View source ↗

Summary

Pfizer is conducting a Phase 3 study of abrocitinib in children aged 6 to less than 12 years with moderate-to-severe eczema, and the trial is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Abrocitinib (abrocitinib)

Snippet

Sponsor: Pfizer | Conditions: Eczema | Phase 3 | Status: RECRUITING